Acquired Hemophilia A In Adults: A Multicenter Study from Turkey

• Published in: Indian journal of hematology & blood transfusion Vol. 39; no. 1; pp. 107 - 115
• Main Authors: Arslan Davulcu, Eren, Demirci, Zühal, Yılmaz, Umut, Ar, Muhlis Cem, Teke, Hava Üsküdar, Karakuş, Volkan, Çiftçiler, Rafiye, Selim, Cem, Yavaşoğlu, İrfan, Durusoy, Salih Sertaç, Okan, Vahap, Akdeniz, Aydan, Yolcu, Alkım, Aydoğdu, İsmet, Güney, Tekin, Yılmaz, Asu Fergün, Şahin, Fahri
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01-01-2023; Springer Nature B.V
• Subjects: Adults; Autoimmune diseases; Blood Transfusion Medicine; Clinical outcomes; Demographics; Epidemiology; Hematology; Hemophilia; Hemorrhage; Human Genetics; Immunotherapy; Medical diagnosis; Medical treatment; Medicine; Medicine & Public Health; Monoclonal antibodies; Oncology; Original; Original Article; Patients; Side effects; Turkey; Other coagulation inhibitors; Acquired coagulation disorders; Hemophilia and other bleeding disorders
• ISSN: 0971-4502; 0974-0449; 0974-0449; 0971-4502
• DOI: 10.1007/s12288-022-01556-8

Acquired hemophilia A (AHA) is a rare disease caused by autoantibodies inhibiting factor VIII (FVIII) activity. Although the conditionis usually idiopathic, there may be other underlying diseases. Treatment consists of two steps: treatment of acute bleeding and immunosuppression. In this multicenter study, we aimed to demonstrate the clinical characteristics, management details, and survival of AHA patients in Turkey. Data was collected from eleven centers in Turkey. aPTT, FVIII, FVIII inhibitor, and hemoglobin (HB) levels, mixing test results, and demographics at diagnosis, treatment information, adverse events, bleeding episodes during follow-up, relapses, and outcome were analyzed. Twenty-nine patients were analyzed (58.6% female). No underlying disorder could be detected in 14 patients. The most prevalent etiologies were pregnancy, malignancy and infections. The median FVIII activity and FVIII inhibitor titer at diagnosis were 0.7% (0.0–29.4%) and 32.6 BU (0.6–135.6 BU) respectively. Bleeding was severe in 44.8% of patients. The HB value was significantly lower in patients with severe bleeding. Most of the patients (n = 25, 86.2%) had only one bleeding episode without relapse, three patients (10.3%) had two bleeding episodes, and one patient had more than three bleedings. 21 (75%) patients received hemostatic therapy. The use of recombinant FVIIa was slightly higher than activated prothrombin complex concentrate (15 versus 10 patients). Immunosuppressive treatment was initiated in 26 (93%) patients. Regimens containing steroid, cyclophosphamide, and rituximab in different combinations were the most preferred. The median follow-up period was 13 months (2–156 months). Median overall survival was 154.97 months. Four and six-year survival were 90.9 ± 0.8% and 77.9 ± 14.1% respectively. This is a unique study that investigated the demographic characteristics, treatment approaches, and patient survival of AHA in Turkey.